Your shopping cart is empty

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

Check out our free and informative ezines and sign up now

Home > Newsletters > Drug Industry Daily > Jazz Gets Warning Letter for Minimizing Risks of Schizophrenia Drug in Patient Promo

Drug Industry Daily

Sept. 21, 2012 | Vol. 11 No. 186

Jazz Gets Warning Letter for Minimizing Risks of Schizophrenia Drug in Patient Promo

Jazz Pharmaceuticals received an FDA warning letter for overstating the benefits and minimizing or omitting the risks of its schizophrenia drug FazaClo in a patient brochure.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
Email This Article
RSS
Free Trial
Archives
Sample PDF

Arbor Receives First FDA Drug Approval Teva Cited for Misleading Clozapine Promotional Material Teva Cited for Misleading Antipsychotic Drug Promotional Material Alcon Sales Aid Draws Untitled Letter for Overstating Efficacy

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.